Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cassava Dives Again After Investors Spooked By Alzheimer’s Drug Fraud Claims

Lab Test Company Did Not Conduct Data Analysis

Executive Summary

Cassava’s claims that its drug reversed cognitive decline in Alzheimer’s patients are seen as "too good to be true" by skeptics. A statement by former lab services partner Quanterix has further undermined investor confidence.

You may also be interested in...



Plagued By Controversy, Promising Alzheimer's Treatment, 2024 To Be Pivotal For Cassava Sciences

All eyes will be on Cassava Sciences in 2024, as it completes two Phase III trials of its closely watched Alzheimer’s disease candidate, simufilam. The drug has been the subject of both skepticism and enthusiasm. 

Cassava’s Simufilam Continues To Alienate Investors Despite Some Phase II Alzheimer’s Promise

The US firm is touting top-line data from an open-label Alzheimer’s disease trial as a net positive, but the lack of p-values and a declining trend in efficacy left some investors and analysts lukewarm.

US FDA Quashes Citizen Petition Against Bluebird’s Zynteglo That Cited Patent, Safety Concerns

San Rocco, whose potential rival gene therapy for thalassemia is in preclinical development, had wanted FDA to delay approval of bluebird’s BLA until resolution of a patent case and a ‘careful investigation’ of Zynteglo’s risks.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC144973

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel